SEOUL (Reuters) - Samsung BioLogics said in a regulatory filing on Thursday that a report saying Samsung Group is in talks to acquire U.S. drugmaker Biogen Inc is not true.
South Korean newspaper Korea Economic Daily reported earlier that Samsung is in talks to buy Biogen, citing investment banking sources.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments